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Coagulation factor XIII (FXIII) has a major
role in the final stage of blood coagulation, is im-
portant for wound healing and maintaining preg-
nancy. Severe congenital FXIII deficiency is a rare
disorder with 1 patient in 1–3 million. Untreated,
it causes bleeding events, with intracranial haem-
orrhage being the major cause of death, impaired
wound healing, and abortion. FXIII deficiency was
traditionally diagnosed using the clot solubility
test, but quantitative FXIII activity and antigen as-
says are preferred today. Treatment consists of re-
placement therapy with FXIII concentrates ad-
ministered every 4–6 weeks. The molecular-ge-
netic causes of FXIII deficiency are mutations in
the genes coding for the FXIII A- and B-subunits.
More than 60 mutations distributed throughout
the FXIII A-subunit gene have been identified so
far and 4 mutations in the FXIII B-subunit gene.
The first case of congenital FXIII deficiency was
reported in Switzerland in 1960. In Switzerland we
observed a disproportionately high incidence,
which can be explained in part by a founder effect.
In this article, we summarise general facts on
severe congenital FXIII deficiency, and we charac-
terise all FXIII deficient patients living in Switzer-
land, including the first case described in 1960 who
is a member of a large family originating from the
canton of Uri.
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structure
Factor XIII (FXIII) is the final coagulation fac-
tor of the coagulation cascade. The zymogen cir-
culates in plasma as a tetramer of two catalytic A-
subunits and two carrier B-subunits (A2B2). The A-
subunit consists of 731 amino acids and has a mo-
lecular weight of approx. 83 kDa, the B-subunit
consists of 641 amino acids and has a molecular
weight of approx. 80 kDa. In plasma, all A-subunits
exist in complexed form, whereas there are free B2
homodimers present in plasma. In platelets, mono-
cytes, and macrophages, cellular FXIII occurs only
as A2 homodimer. The B-subunits are synthesised
in the liver by hepatocytes. The A-subunits are as-
sumed to be mainly of bone marrow origin, ie from
megakaryocytes, monocytes and monocyte-de-
rived macrophages, but hepatocytes might also
contribute to plasma FXIII A-subunit synthesis
[1–3]. However, it is not clear how the A-subunits
are released into plasma since they lack a signal
peptide for secretion. It is assumed that the A-sub-
units are released from cells as a consequence of
cell injury, which is independent of the classical se-
cretory pathway [4].
In plasma, thrombin, together with the cofac-
tors fibrin(ogen) and Ca2+, activates FXIII by cleav-
age of the activation peptide from the A-subunit,
followed by dissociation of the A- and B-subunits,
as shown in figure 1. Activated FXIII (FXIIIa),
which is a transglutaminase, covalently cross-links
fibrin polymers in two ways: by γ-dimerisation,
Gln398 of the γ-chain in one fibrin molecule and
Lys406 of the γ-chain in the next fibrin molecule
are cross-linked, and by α-polymerisation, Gln328,
Gln366, and Lys508 of α-chains in multiple fibrin
molecules are cross-linked [1]. In addition, FXIIIa
incorporates antifibrinolytic proteins such as α2-
antiplasmin and thrombin activatable fibrinolysis
inhibitor (TAFI) into fibrin. Only by these reac-
tions the fibrin clot obtains sufficient stability and
becomes resistant to premature fibrinolysis [1–3].
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FXIII plays also an important role in wound
healing and tissue repair [5]. It cross-links proteins
of the extracellular matrix such as fibronectin and
collagen, enhances migration and proliferation of
fibroblasts, modulates macrophage migration and
phagocytosis, and enhances the function of the en-
dothelial barrier. Recently, a direct proangiogenic
effect on endothelial cells in vitro and promotion
of angiogenesis in several in vivo animal models
was described [6]. Furthermore, FXIII is necessary
for the maintenance of pregnancy [7]. Maternal
FXIII-A2 is localised within the placenta at the in-
terface between maternal and foetal tissue, where
it is crucial for the formation of the cytotro-
phoblastic shell and the Nitabuch’s layer. FXIII de-
ficiency leads to poor formation of the cytotro-
phoblastic shell and the fibrinoid layers leading
eventually to detachment of the placenta from the
uterus [8].
Figure 1
Activation and cross-linking reaction of FXIII
After activation of coagulation, thrombin is formed by the
prothrombinase complex consisting of activated factors X
and V (FXa, FVa), calcium ions (Ca2+) and phosholipids (PL)
(blue boxes). Thrombin converts fibrinogen into soluble fib-
rin by cleaving fibrinopeptides A and B (FPA, FPB) (yellow
box) and initiates FXIII activation by cleaving FXIII activation
peptide (red box). FXIII activation is completed by dissocia-
tion of the A- and B-subunit induced by Ca2+. Both FXIII acti-
vation steps are enhanced by fibrinogen and fibrin (Fbg/Fn).
Activated FXIII (FXIIIa) cross-links Lysine (Lys) and Gluta-
mine (Gln) residues of soluble fibrin molecules in a trans-
glutaminase reaction (yellow box).
Severe congenital FXIII deficiency: symptoms and epidemiology
Most patients with severe congenital FXIII de-
ficiency suffer from a severe bleeding diathesis, but
some patients have only mild symptoms. The first
and most characteristic symptom is bleeding from
the umbilical cord several days after birth. Other
frequent bleeding events include superficial bruis-
ing and subcutaneous haematomas, intramuscular
and joint haemorrhage, postoperative haemor-
rhage and bleeding after tooth extraction, and in-
tracranial haemorrhage which is the major cause
of death or disabling consequences. Typically,
bleeding symptoms occur hours or days after
trauma since the initially formed uncross-linked
fibrin clot does not have sufficient stability and is
prematurely dissolved by the fibrinolytic system.
According to the various functions of FXIII, symp-
toms of congenital deficiency are not limited to
bleeding. Many patients suffer from impaired
wound healing and abnormal scar formation, and
women frequently experience spontaneous abor-
tions in the early pregnancy [9–11].
Severe congenital FXIII deficiency is a rare,
autosomal recessive inherited disease that affects
all races and both sexes equally [9]. The incidence
of congenital FXIII deficiency has been estimated
at 1 in 2–5 million in the British population [10,
12] and extrapolated at 1 in 3 million worldwide
[11], which is much lower than haemophilia A (1
in 5000–10000) or haemophilia B (1 in 25000–
30000). However, this low incidence may lead to
unawareness and due to the fact that FXIII defi-
ciency is not diagnosed by the routinely applied co-
agulation tests which detect the appearance of
polymerised fibrin but not its stabilisation by
FXIII, congenital FXIII deficiency may well be un-
derdiagnosed. In Finland, the disease is unusually
common, with 12 affected cases from 8 families in
a total population of 5 million. Molecular-genetic
analysis revealed a particular mutation which was
present in 6 of the 8 families and led to the pro-
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posal of a founder effect being responsible for the
high incidence of FXIII deficiency in the Finnish
population [13]. Generally, a founder effect may be
considered the cause for a high incidence of rare
inherited diseases; a new population established by
only a small number of ancestors may result in an
increase in rare alleles and a loss of genetic varia-
tion. A founder mutation can be evidenced by
studying haplotypes of the respective gene in order
to distinguish a founder mutation from indepen-
dent hot-spot mutations. In addition, the incidence
of severe congenital FXIII deficiency is also in-
creased in populations where consanguineous
marriages are common [10]. 
The first case: a Swiss story
In 1960, Duckert et al. described for the first
time a case of severe congenital FXIII deficiency
in their publication “A hitherto undescribed con-
genital haemorrhagic diathesis probably due to
fibrin stabilising factor deficiency” [14]. They re-
ported on a seven-year old Swiss boy who had al-
ready been hospitalised for surgical intervention of
umbilical bleeding, treatment of a large
haematoma on the head, trepanation of a subdural
haematoma, a laceration and contusion on the
head, and another contusion on the head. Bleed-
ing occurred usually 24–36 hours after injury. His
blood clots were loose and prone to rebleeding. He
suffered from extremely slow and poor wound
healing with wounds bleeding for weeks despite
surgical intervention and compressive bandages.
Wound healing took several weeks with the forma-
tion of a loose granulation tissue and resulted in
extensive, irregular, and retracted scars. Labora-
tory analysis including bleeding time, Quick,
thrombocytes, extrinsic and intrinsic coagulation
factors, and the fibrinolytic system gave normal re-
sults.
The boy was the third son of consanguineous
parents. His younger brother showed the same
bleeding tendency, but his four other siblings and
his parents were not affected. Further research on
the family history revealed that two brothers of the
maternal grandfather had died from severe bleed-
ing events, and three female second cousins of the
patient were also affected, of who two already died.
Based on the delayed bleeding episodes, the
obvious lability of the patient’s blood clots, and fi-
nally the clot solubility in 5 M urea, Duckert et al.
suggested the deficiency of the fibrin stabilising
factor which had been first described by Laki and
Lorand in 1948 [15].
Today, the first patient is fortunately still in
good health and took part in our recently pub-
lished study on molecular characterisation of this
first described FXIII deficient patient 47 years
after diagnosis [16].
Severe congenital FXIII deficiency in Switzerland
In Switzerland, there is a disproportionately
high incidence of severe congenital FXIII defi-
ciency, with 14 patients in approximately 7.5 mil-
lion inhabitants. Table 1 summarises the charac-
teristics of these patients. Five patients are from
central Switzerland, three from the canton of 
Bern, one patient is from Geneva, and five patients
are originally from Eastern European countries.
Figure 2
Pedigree of the tribe from the canton of Uri,
from 1600 until today
Latin numbers represent the generations. 
Circle: female. Square: male. Filled symbols:
individuals who are homozygous for FXIII 
deficiency and therefore affected by the dis-
ease. Semi-filled symbols: individuals who are
heterozygous and therefore only carrier of the
disease but not affected [17]. The five patients
with severe FXIII deficiency taking part in our
molecular-genetic analysis are indicated with
red arrows (homozygous) or with a red circle
(double heterozygous patient).
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The age at diagnosis varies markedly between 5
days and 22 years. The younger Swiss patients
were diagnosed at a younger age due to a better
awareness of the disease. All patients have experi-
enced several of the typical bleeding events. Except
for three patients, all are under regular prophylac-
tic replacement therapy. 
The cluster of congenital FXIII deficiency in
central Switzerland has been investigated in a ge-
nealogical study by Durrer [17]. Studying old
church registers, medical records, and family mem-
ories, he succeeded to trace back the hereditary dis-
ease to two ancestors in the 17th century and to re-
construct the complete pedigree of this tribe origi-
nating from the canton of Uri, as shown in figure
2. Durrer showed the familial relationship between
the five patients from central Switzerland due to
consanguineous marriages within the tribe and
therefore proposed a founder effect for FXIII defi-
ciency in this group of patients without knowledge
of their molecular genetics. Between the other four
Swiss patients there exist no known familial rela-
tionships. The remaining five patients are all origi-
nally from Eastern European countries, thus, a
founder effect might also be involved. Since the mo-
lecular-genetic basis of FXIII deficiency in these 14
patients living in Switzerland, including the first de-
scribed patient, has been unknown so far, we per-
formed the molecular-genetic analysis to identify
the causing mutations in the FXIII genes [16].
Figure 3
Structural analysis of the mutation Arg77Cys
found in the tribe of Uri
Left: FXIII A2 homodimer (the two monomers
are displayed in yellow and blue). Wild-type
Arg77 is located at a critical site between the 
b-sandwich and core-domain.
Right: Top: Wild-type Arg77 (green) forms 
hydrogen bonds (yellow dashes) with His65
and Phe184.
Bottom: Mutant Cys77 (green) forms no 
hydrogen bonds and leaves an open gap.
(Modified from [16] and reproduced with 
permission from the publisher) 
Molecular-genetic cause of FXIII deficiency
Two different genes code for the two FXIII
subunits [1]. The gene coding for the A-subunit is
located on chromosome 6, p24-25. It spans 160 kb
and consists of 15 exons separated by 14 introns.
The gene coding for the B-subunit is located on
chromosome 1, q31-32.1. It spans 28 kb and con-
sists of 12 exons and 11 introns. The molecular-
genetic causes of congenital FXIII deficiency are
mutations in the FXIII genes. More than 60 mu-
tations in the A-subunit gene, and 4 mutations in
the B-subunit gene, have been identified so far
[18]. Approximately one third of the A-subunit
gene mutations and two of the B-subunit gene mu-
tations have been expressed in mammalian or yeast
cell culture in order to support their causative na-
ture in FXIII deficiency. Most of the mutations
code for a single amino acid exchange (missense
mutations) resulting in defective folding and insta-
bility of the mutant protein. In addition, mutations
leading to stop codons (nonsense mutations), small
deletions/insertions leading to frameshift and con-
sequently to premature stop codons, and intronic
mutations at splice sites leading to incorrect post-
transcriptional processing of the messenger RNA
(mRNA) have been reported. In the A-subunit
gene, missense mutations occur in all exons except
exons 1 and 13, and splice site mutations occur in
introns 3, 5, 7, 8, 10, 11, and 14.
When we investigated the 14 FXIII deficient
patients living in Switzerland, we identified ten
different mutations in the A-subunit gene (table 1),
among them four mutations which had been de-
scribed previously and six novel mutations [16]. By
cell expression of wild-type FXIII A-subunit and
the mutant variants Arg77Cys, Met159Arg,
Gly215Arg, Trp375Cys, and His716Arg, we con-
firmed their causative nature in FXIII deficiency.
Our molecular-genetic analysis also confirmed the
familial relationship between the five patients from
central Switzerland, which Durrer [17] had de-
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duced from his large pedigree. These five patients,
including the first case described in 1960, carry a
point mutation in exon 3, codon 77 of the FXIII
A-subunit gene, resulting in the exchange of the
amino acid arginine (Arg) by cysteine (Cys). Ex-
pression of the mutant Cys77 protein in cell cul-
ture yielded only traces of FXIII A-subunit protein
(less than 1% of the Cys77 mutant compared to
wild-type), confirming that this Arg77Cys muta-
tion was causative for FXIII deficiency. Structural
analysis (figure 3) revealed that the wild-type
Arg77 forms hydrogen bonds with two neighbour-
ing amino acids and therefore may have an impor-
tant role in stabilisation of the protein structure.
The mutant Cys77, however, does not maintain
these hydrogen bonds and leaves an open gap be-
cause of its smaller side chain. It is therefore likely
to destabilise the environment leading to defective
folding and/or premature decay of the FXIII pro-
tein. Durrer also predicted that four patients were
homozygous for one mutation, whereas one pa-
tient had to be compound heterozygous carrying
two different mutations from his father and
mother side, since his mother is of different origin.
We could also confirm this prediction and showed
that four patients are indeed homozygous for the
Arg77Cys mutation, and that one patient has the
Arg77Cys mutation on one allele and a deletion of
a guanosine (G) nucleotide in codon 202, Glu202
delG, on the other allele. This deletion induces a
shift of the reading frame during the translation
process resulting in a premature stop codon five
codons downstream. Consequently, the major part
of the FXIII A-subunit polypeptide including the
essential active site region is not translated from
mRNA into protein. The Glu202 delG mutation
has not been described so far. Interestingly, the
Arg77Cys mutation has also been found in Chi-
nese patients [19]. For more information on the
other mutations found in the Swiss patients please
refer to our original publication [16].
Diagnosis and treatment
Diagnosis of congenital FXIII deficiency can-
not always been made right after birth since the
severity of clinical signs can differ between indi-
viduals and major bleeding episodes do not always
occur in the first weeks of life. However, because
of the potentially fatal bleeding complications, the
possible diagnosis of severe congenital FXIII defi-
ciency should not be delayed in any individual with
an unknown bleeding tendency.
However, laboratory analysis of FXIII activity
and/or antigen levels is not available everywhere.
Because FXIII acts when fibrin has already been
formed, it is not detected by routine coagulation
assays. In the past, severe FXIII deficiency could
only be diagnosed using the clot solubility test. In
this test, plasma samples are allowed to clot and the
clot is then resuspended in diluted urea or mono-
chloroacetic acid solutions. Presence of FXIII
makes the clot insoluble whereas dissolution of the
clot indicates FXIII deficiency. This assay allows
only semi-quantitative FXIII determination. Ad-
ditionally, careful consideration of the preanalytic
condition is mandatory, since any plasma or FXIII
administration within the weeks before testing will
give “normal” results, with some 5% of normal
FXIII plasma concentration already being suffi-
cient for giving a urea-resistant clot. For these rea-
sons, quantitative FXIII activity and antigen assays
are more recommended. The most commonly
used commercial assay, Berichrom® FXIII (by
Dade Behring AG, Marburg, Germany), is based
on a photometric method and can be carried out
on several automatic coagulation analysers. The
assay has one disadvantage: it may give too high re-
sults in the low FXIII range due to interference
with high ammonia concentrations in the test
plasma, what can be avoided by doing mixing stud-
ies with normal plasma. Therefore, FXIII activity
levels below 15% obtained with this assay should
be carefully reviewed as there might be no or only
traces of FXIII in the sample. For this reason, we
recommend the Pefakit® FXIII Incorporation
Assay (by Pentapharm Ltd, Basel, Switzerland) or
enzyme-linked immunosorbent assay (ELISA)
methods for determination of FXIII activity or
FXIII antigen levels, respectively, especially for di-
agnosis or therapy monitoring of FXIII deficiency.
The Pefakit® FXIII Incorporation Assay measures
FXIII cross-linking activity and the ELISAs di-
rectly detect the FXIII A-subunit or B-subunit
proteins by specific antibodies. Both Pefakit® and
ELISAs are highly sensitive and therefore reliable
in the low range. Unfortunately, these methods are
quite time-consuming and cannot be carried out
automatically, and the ELISAs are mainly in-house
assays. Unlike in haemophilia A and B, in severe
FXIII deficiency there exist no different degrees of
severity relating to residual FXIII activity and/or
antigen plasma levels, since FXIII deficiency caus-
ing mutations always lead to complete absence of
the protein. So far, no cases of only partially re-
duced FXIII activity and/or antigen levels are
known.
If the diagnosis of severe congenital FXIII de-
ficiency is confirmed, prophylactic replacement
therapy is mandatory because of the sometimes
fatal or severely disabling bleeding complications
after only minor trauma. The treatment normally
consists of prophylactic administration of FXIII
concentrate, commercially available as Fibrogam-
min® HS (by ZLB Behring, Bern, Switzerland). 
In prophylaxis studies this concentrate has proven
to be efficient in bleeding control and safe with no
development of inhibitors or viral seroconversion
[20]. Thanks to the long half-life of FXIII in
plasma, approximately 10 days, it is sufficient to
administer FXIII concentrate only every 4–6
weeks. With regular replacement therapy, patients
can lead a normal life. Under special conditions, eg
pregnancy or surgical interventions, FXIII levels
should be monitored more closely as higher or
more frequent dosage of FXIII may be required
[21, 7]. Recently, recombinant FXIII products
have been developed and first clinical trials have
been carried out [22, 23]. Heterozygous carriers of
FXIII deficiency have about 50% of normal FXIII
plasma levels and usually do not need any therapy
since their haemostasis functions normally under
most conditions.
International registry
Since April 2006, the international registry on
severe congenital FXIII deficiency is open to the
public on the World Wide Web under
http://www.f13-database.de. The registry is main-
tained by V. Ivaskevicius and J. Oldenburg, Uni-
versity of Bonn, Germany, and supported by the
Factor XIII and Fibrinogen Subcommittee of the
Scientific and Standardisation Committee (SSC),
which serves as the scientific working arm of the
International Society on Thrombosis and
Haemostasis (ISTH). The aim of this registry is to
collect data on all FXIII deficient patients to gain
more knowledge on this rare hereditary disease. In
addition, the website provides detailed informa-
tion on FXIII and FXIII deficiency.
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